ApoB (Apolipoprotein B)

What it is

Each atherogenic lipoprotein particle (VLDL, IDL, LDL, Lp(a)) carries exactly one apolipoprotein B molecule on its surface. Measuring apoB therefore counts the number of atherogenic particles directly, rather than the cholesterol mass they carry (LDL-C).

Why it’s preferred over LDL-C

When LDL-C and apoB disagree (“discordant” lipid profiles), cardiovascular outcomes track apoB. Discordance is common in:

• Hypertriglyceridaemia (small dense LDL).
• Metabolic syndrome.
• Some chronic kidney disease.

Target levels

There is no “normal range” for apoB in the population-health sense. The question is: what level corresponds to acceptable lifetime cardiovascular risk? Modern recommendations:

• Primary prevention, average risk: <90 mg/dL.
• Higher risk / family history: <80 mg/dL.
• Secondary prevention / very high risk: <65 mg/dL.

These are tighter than legacy LDL-C targets.

What lowers apoB

• Statins.
• Ezetimibe.
• PCSK9 inhibitors.
• Bempedoic acid.
• Dietary saturated-fat reduction.
• GLP-1 agonists (modest).
• Weight loss (modest).

More on this topic

• LDL Cholesterol (LDL-C) — Biomarker.
• Statins vs PCSK9 Inhibitors — Comparison.
• HDL Cholesterol (HDL-C) — Biomarker.
• Non-HDL Cholesterol — Biomarker.
• Triglyceride/HDL Ratio — Biomarker.

Related entries

Statins, Lp(a), Cardiovascular disease.